Who
Arnold C. Hanish
Director
Company insider
Files Form 4 as: Director, Decoy Therapeutics; Director, Omeros; Chief Accounting Officer, Eli Lilly and.
In numbers
- Trades disclosed
- 91
- Buys
- 11
- Sells
- 9
- Bought
- $76K
- Sold
- $1.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 20 Jan 2006
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $40K2,500 at $15.81 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $110K7,500 at $14.66 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $94K5,000 at $18.88 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $95K5,000 at $19.02 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $40K2,500 at $15.81 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $110K7,500 at $14.66 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $94K5,000 at $18.88 | filing |
| 27 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $95K5,000 at $19.02 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $79K5,000 at $15.81 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $93K5,000 at $18.53 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $79K5,000 at $15.81 | filing |
| 26 Aug 2026filed 28 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $93K5,000 at $18.53 | filing |
News
Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab OpinionOMER · rttnews.com · 16 Oct 2026
0 headlines in the last 90 days name Arnold C. Hanish; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.